INCR INC Research Holdings Inc

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against INC Research Holdings, Inc. – INCR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) from May 10, 2017 through November 9, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for INC Research investors under the federal securities laws.

To join the INC Research class action, go to http://rosenlegal.com/cases-1236.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) the merger with inVentiv Health, Inc. (“inVentiv”) was not providing the benefit that defendants stated it would; (2) inVentiv was underperforming; (3) in turn, INC Research’s 2017 financial performance would be negatively impacted; and (4) as a result, defendants’ statements about INC Research’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 30, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1236.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

Kevin Chan, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 34th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

EN
04/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INC Research Holdings Inc

 PRESS RELEASE

Syneos Health Closes Transaction with Private Investment Firms

Syneos Health Closes Transaction with Private Investment Firms Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers MORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As a result of the...

 PRESS RELEASE

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Syneos Health Names Terttu Haring President, Clinical Sites & Patients Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organizat...

 PRESS RELEASE

Syneos Health and Oracle to Expand Relationship to Accelerate Patient ...

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient pop...

 PRESS RELEASE

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Bill...

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Hea...

 PRESS RELEASE

Syneos Health Stockholders Approve Agreement with Private Investment C...

Syneos Health Stockholders Approve Agreement with Private Investment Consortium MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier toda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch